Children's Medical Center Corporation

Whitehead Institute for Biomedical Research

Harvard College

The General Hospital Corporation

Institut Pasteur

Other

The Johns Hopkins University

Howard Hughes Medical Institute

Institute Pasteur

Massachusetts Institute of Technology

The Brigham and Women's Hospital, Inc.

New England Medical Center Hospitals. Inc.

Cell Genesys, Inc.

Somatix Therapy Corporation

Howard Hughes Medical Center

Richard C Mulligan

James M Wilson

André Choulika

Jeng-Shin Lee

Lawrence K Cohen

Bob Carter

Lori F Rafield

Szofia S Bullain

Jeffrey R Morgan

Drew M Pardoll

George J Murphy

Alejandro Benjamin Balazs

Glenn Dranoff

Brad Guild

Olivier Danos

Louis K Birinyi

Robert Samuel Langer

Andre Choulika

Paul David Robbins

John T Gray

Paul B Robbins

John A Young

Bernhard G Mueller

Laising Yen

Sachiko Hirosue

Isabelle Riviere

Sophie Snitkovsky

Thomas M Niederman

Allan D Callow

Graham J Lieschke

Isabelle Rivi&egrave;re

Provided are chimeric VEGF-binding proteins and nucleic acids (e.g., a vector) encoding chimeric VEGF-binding proteins, methods and host cells for producing these proteins and nucleic acids, and pharmaceutical compositions containing these proteins and nucleic acids. Also provided are methods of treating an angiogenic disease or disorder that include administering at least one of the chimeric VEGF-binding proteins or at least one of the nucleic acids (e.g., a vector) encoding a chimeric VEGF-binding protein.

VEGF-binding protein for blockade of angiogenesis

In certain embodiments, the disclosure relates to compositions and methods relating to a translation-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to methods of regulating gene expression via modulating translation termination.

Methods and compositions for regulating gene expression

In certain embodiments, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs.

Self-cleaving ribozymes and uses thereof

Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases.

Chromosomal modification involving the induction of double-stranded DNA cleavage and homologous recombination at the cleavage site

Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases.

Described herein are methods for purifying hematopoietic stem cells. Also described herein are methods for purifying EPCR+ cells. The invention also provides substantially pure isolated hematopoietic stems cells, including EPCR+ hematopoietic stem cells.

Populations of hematopoietic stem cells

Methods for purifying hematopoietic stem cells

Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof.

Gene repair involving in vivo excision of targeting DNA

Novel packaging cell lines useful for generating viral accessory protein independent HIV-derived retroviral vector particles, methods of constructing such packaging cell lines and methods of using the viral accessory protein independent HIV-derived retroviral vector particles are disclosed.

Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins

Retroviral vectors are disclosed which include an insertion site for genes of interest and are capable of expressing high levels of the protein derived from the genes of interest in a wide variety of transfected cell types. Also disclosed are retroviral vectors lacking a selectable marker, thus rendering them suitable for human gene therapy in the treatment of a variety of disease states without the co-expression of a marker product, such as an antibiotic. These retroviral vectors are especially suited for use in certain packaging cell lines.

Retroviral gene therapy vectors and therapeutic methods based thereon

Growing community of inventors

Cambridge, MA, United States of America

Richard C Mulligan